Your browser doesn't support javascript.
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Tut, Gokhan; Lancaster, Tara; Krutikov, Maria; Sylla, Panagiota; Bone, David; Kaur, Nayandeep; Spalkova, Eliska; Bentley, Christopher; Amin, Umayr; Jadir, Azar T; Hulme, Samuel; Butler, Megan S; Ayodele, Morenike; Bruton, Rachel; Shrotri, Madhumita; Azmi, Borscha; Fuller, Chris; Irwin-Singer, Aidan; Hayward, Andrew; Copas, Andrew; Shallcross, Laura; Moss, Paul.
  • Tut G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Lancaster T; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Krutikov M; UCL Institute of Health Informatics, University College London, London, UK.
  • Sylla P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Bone D; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Kaur N; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Spalkova E; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Bentley C; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Amin U; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Jadir AT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Hulme S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Butler MS; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Ayodele M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Bruton R; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Shrotri M; UCL Institute of Health Informatics, University College London, London, UK.
  • Azmi B; UCL Institute of Health Informatics, University College London, London, UK.
  • Fuller C; UCL Institute of Health Informatics, University College London, London, UK.
  • Irwin-Singer A; Department of Health and Social Care, London, UK.
  • Hayward A; Health Data Research UK, London, UK.
  • Copas A; UCL Institute for Global Health, University College London, London, UK.
  • Shallcross L; UCL Institute of Health Informatics, University College London, London, UK.
  • Moss P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Lancet Healthy Longev ; 2(9): e544-e553, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1433991
ABSTRACT

Background:

Residents of long-term care facilities (LTCFs) have been prioritised for COVID-19 vaccination because of the high COVID-19 mortality in this population. Several countries have implemented an extended interval of up to 12 weeks between the first and second vaccine doses to increase population coverage of single-dose vaccination. We aimed to assess the magnitude and quality of adaptive immune responses following a single dose of COVID-19 vaccine in LTCF residents and staff.

Methods:

From the LTCFs participating in the ongoing VIVALDI study (ISRCTN14447421), staff and residents who had received a first dose of COVID-19 vaccine (BNT162b2 [tozinameran] or ChAdOx1 nCoV-19), had pre-vaccination and post-vaccination blood samples (collected between Dec 11, 2020, and Feb 16, 2021), and could be linked to a pseudoidentifier in the COVID-19 Data Store were included in our cohort. Past infection with SARS-CoV-2 was defined on the basis of nucleocapsid-specific IgG antibodies being detected through a semiquantitative immunoassay, and participants who tested positive on this assay after but not before vaccination were excluded from the study. Processed blood samples were assessed for spike-specific immune responses, including spike-specific IgG antibody titres, T-cell responses to spike protein peptide mixes, and inhibition of ACE2 binding by spike protein from four variants of SARS-CoV-2 (the original strain as well as the B.1.1.7, B.1.351, and P.1 variants). Responses before and after vaccination were compared on the basis of age, previous infection status, role (staff or resident), and time since vaccination.

Findings:

Our cohort comprised 124 participants from 14 LTCFs 89 (72%) staff (median age 48 years [IQR 35·5-56]) and 35 (28%) residents (87 years [77-90]). Blood samples were collected a median 40 days (IQR 25-47; range 6-52) after vaccination. 30 (24%) participants (18 [20%] staff and 12 [34%] residents) had serological evidence of previous SARS-CoV-2 infection. All participants with previous infection had high antibody titres following vaccination that were independent of age (r s=0·076, p=0·70). In participants without evidence of previous infection, titres were negatively correlated with age (r s=-0·434, p<0·0001) and were 8·2-times lower in residents than in staff. This effect appeared to result from a kinetic delay antibody generation in older infection-naive participants, with the negative age correlation disappearing only in samples taken more than 42 days post-vaccination (r s=-0·207, p=0·20; n=40), in contrast to samples taken after 0-21 days (r s=-0·774, p=0·0043; n=12) or 22-42 days (r s=-0·437, p=0·0034; n=43). Spike-specific cellular responses were similar between older and younger participants. In infection-naive participants, antibody inhibition of ACE2 binding by spike protein from the original SARS-CoV-2 strain was negatively correlated with age (r s=-0·439, p<0·0001), and was significantly lower against spike protein from the B.1.351 variant (median inhibition 31% [14-100], p=0·010) and the P.1 variant (23% [14-97], p<0·0001) than against the original strain (58% [27-100]). By contrast, a single dose of vaccine resulted in around 100% inhibition of the spike-ACE2 interaction against all variants in people with a history of infection.

Interpretation:

History of SARS-CoV-2 infection impacts the magnitude and quality of antibody response after a single dose of COVID-19 vaccine in LTCF residents. Residents who are infection-naive have delayed antibody responses to the first dose of vaccine and should be considered for an early second dose where possible.

Funding:

UK Government Department of Health and Social Care.

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Language: English Journal: Lancet Healthy Longev Clinical aspect: Etiology Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Language: English Journal: Lancet Healthy Longev Clinical aspect: Etiology Year: 2021
...